Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Among more than 500 women who presented for a screening mammography during a 6-month period in 2023, just 4% of survey ...

Regular breast screenings are a crucial tool in the early detection of breast cancer, as they significantly increase the ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Recent statistics from the American Cancer Society reveal an increase in diagnoses of breast cancer among young women. We ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

Breast cancer is the leading cause of cancer death among Latinas. Testing for breast density and other risk factors can save ...

The annual cancer statistics report from the National Cancer Institute (NCI) — which was published in the journal Cancer on ...

The spirit of Motown lit up Rivington Hall Barn in Bolton as Boot Out Breast Cancer hosted their annual Ladies’ Lunch on Thursday, April 3, 2025.